Journal
BRITISH JOURNAL OF CANCER
Volume 114, Issue 4, Pages 357-361Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.481
Keywords
virotherapy; targeted oncolytic vaccines; systemic delivery; tumour-specific viruses; pro-inflammatory; self-amplifying therapeutic agent
Categories
Funding
- Cancer Research UK [C552/A177020]
- Cancer Research UK [17720] Funding Source: researchfish
Ask authors/readers for more resources
Oncolytic viruses can be found at the confluence of virology, genetic engineering and pharmacology where versatile platforms for molecularly targeted anticancer agents can be designed and optimised. Oncolytic viruses offer several important advantages over traditional approaches, including the following. (1) Amplification of the active agent (infectious virus particles) within the tumour. This avoids unnecessary exposure to normal tissues experienced during delivery of traditional stoichiometric chemotherapy and maximises the therapeutic index. (2) The active cell-killing mechanisms, often independent of programmed death mechanisms, should decrease the emergence of acquired drug resistance. (3) Lytic death of cancer cells provides a pro-inflammatory microenvironment and the potential for induction of an anticancer vaccine response. (4) Tumour-selective expression and secretion of encoded anticancer biologics, providing a new realm of potent and cost-effective-targeted therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available